

# Q2FY21 Result Update@ Dalal&Broacha

ACCUMULATE	
Current Price	175
Target Price	198
Upside	13%
52 Week Range	101/391

Key Share Data	
Market Cap (Rs.Bn)	89
Market Cap (US\$ Mn)	1208
No of o/s shares (Mn)	509
Face Value	10
BSE Code	540065
NSE Code	RBLBANK
Bloomberg	RBK:IN



% Shareholding	Sep-20	Jun-20
Promoters	0.00	0.00
FII	30.62	29.28
DII	19.13	22.44
Others	50.25	48.27
Total	100	100

#### RBL Bank has reported a stable set of numbers for the guarter ended September 2020.

- NII came in at INR 9321 Mn, -10.5% QoQ / +7.3% YoY.
- Other Income came in at INR 4562 Mn, +36.9% QoQ / +3.3% YoY.
- PPOP came in at INR 7198 Mn, +4.4% QoQ / +13.2% YoY.
- Provisions came in at INR 5256 Mn, 5.1% QoQ / -1.4% YoY.
- PAT came in at INR 1442 Mn, 2.1% QoQ / 165% YoY.
- EPS stood at INR 2.83 vs INR 2.78 / INR 1.26 in Q1FY21 / Q2FY20 respectively.

#### **Financial Highlights**

- Bank's loan book declined by 4% YoY/0.9% QoQ, as wholesale loans shrank 26% YoY. Bank has cautiously avoided taking bulky loan exposures in the last few quarters as it is looking to brought NPAs under control which had spiked last fiscal due to loan exposures to CCD and few stressed companies in the media & real estate sectors. Non-Wholesale loans grew 23% YoY as credit card loans grew 41% YoY, while other retail sub-segments saw much softer growth.
- On liabilities, Deposits grew by 3% YoY/4% QoQ in Q2FY21 led by CASA growth of 21% YoY/8% QoQ taking CASA ratio at 31.1% (Vs 26.5% YoY).
- Bank's asset quality improved during the quarter, with GNPAs sequentially down by 11 bps at 3.34% and NNPAs down by 27 bps to 1.38% on account of standstill levied by the Supreme Court. Excluding the same, GNPAs would have been 3.49% and NNPA would have been 1.49% as per the proforma approach (recognition of NPA using analytical models). Bank is keeping COVID related provisions of Rs 3.1 Bn in Q2FY21; total cumulative provisions of Rs. 6.64 Bn (121 bps of advances).
- ~ 9% of the credit card portfolio is currently overdue which includes ~5% of advances that have not paid a single due since April. Management estimates credit costs in credit card/micro finance portfolio at ~9-10%/4-5% and continues to maintain overall credit cost guidance at around last year levels for FY21.
- The bank's operational efficiency remained strong, with cost to income ratio falling by 332 bps YoY to 48.2%, backed by higher net income (NII + other income) growth of 6% vs opex de-growth of 0.9% in Q2FY21.

## Valuation and outlook

Even though Asset Quality is likely to remain under pressure in near term, we take comfort from its tier-1 capital ratio (15.1%) and COVID related provisions of Rs 6.64 Bn (1.21% of advances), which provide an additional buffer to cushion any adverse effect of sudden spikes in slippages. Bank is continuously focusing on de-risking its balance sheet and improving granular liability franchise, which also witnessed in current quarter. As confidence improves on balance sheet, we should see valuations improve from current levels. We expect the bank's RoA/RoE to be around 0.7%/5% in FY21 and recover back to 1.3%/9.9% in FY22. At CMP the stock trades at 0.9x its FY21E ABV and 0.8x its FY22E ABV. We assign ACCUMULATE rating with Target Price of Rs 198/share, valuing the stock at a target multiple of 0.9x FY22E ABV.

Consolidated Financials (In INR Bn)									
Year	NII	PPOP	PAT	ROA	ROE	Adj BVPS	P/BVPS		
FY20	36.3	27.5	5.1	0.6	5.6	185	0.9		
FY21E	38.9	29.2	6.1	0.7	5.3	196	0.9		
FY22E	46.2	35.1	13.1	1.3	9.9	217	0.8		



# Q2FY21 Result Update@ Dalal&Broacha

#### **Highlights of the Conference Call**

#### Asset quality

- The gross slippage without availing the benefit of the standstill to asset classification would have been Rs. 2.35 Bn (vs reported Rs 1.45 Bn) and the gross slippage ratio would have been 1.07%.
- Over & above 0.63% contingency buffer, the bank built further provisions Rs 3.1 bn towards loans under moratorium, taking cumulative provision buffer of Rs 6.64 bn (1.21% of loans).
- In terms of credit provisioning indication for FY21, it would remain within the same ballpark of ~5% as last year.
- Bank's credit filters continue to remain extremely conservative, and are looking at every client in terms of their current cash flows, prepayment on their existing deals across finances, especially during moratorium, and a degree of certainty in terms of future business
- Bank's collection efficiency stood 93% of pre COVID levels in Sep 2020 and improving every month, and management expect it to reach pre COVID levels by Jan 2021.

#### Capital adequacy

- Bank has received approval from RBI to go ahead with the capital raise of Rs 15.66 Bn, which is pending approval because of 1 large shareholder wanting to be above 5%.
- The completing of this capital raise over the next few days will increased adequacy ratio to 18.7% (vs 16.5% in Q2FY20), with a CET1 of 17.4%.

## **MSME** business

- Bank has disbursed ~ Rs 4.50 Bn under ECLGS, a little under 80% of what the bank expected to disburse by Dec 2020. This also results in some de-risking of portfolio as it has given much needed working capital to these businesses, trying to get back to normalcy.
- Business loans are still a little slow at about 65% of BAU volumes. The recovery here will take slightly longer and is a function of businesses being able to recover fully in terms of sales.

## **Credit Card segment**

- The bank's moratorium book in credit card segment came down from 22% (by value) and 11% (by customers) in June to 16% (by value) and 9% (by customers) as on August '20. Bank is seeing a monthly reduction of 10% to 12% on this pool, which is likely to continue through quarter. Bank is confident of restricting credit cost on the portfolio to ~ 9% 10% as earlier guided.
- As of Sep 30, 9.4% of the portfolio was overdue, out of which 54% customers have not paid since April or May. Most of its credit losses will come from this 54% customers. Management is expecting a credit cost on this portfolio to be~ 9%-10%.
- New card issuance is gaining momentum, with bank issuing close to 100,000 cards in Sep 2020. Management is confident that they will achieve pre COVID run rate by December end and then grow from there.
- Discretionary spends higher than March levels partly on account of pent up demand. Daily spends at 96% of March levels.

### Wholesale business

- Bank is focusing on adding better quality names and keeping granularity in its portfolio.
- The borrowers rated A minus or better are now 75.1% of rated portfolio, and this reflects a consistent improvement over the last several quarters.
- Bank has added 60 new client relationships in the quarter across product segments of cash management services, digital banking, advances and liabilities.

## Micro banking

- The bank is now disbursing around 85% of our BAU (business as usual) run rates.
- ~6.7% of the customers have not paid any installments since April while rest 93.3% have resumed payment. With collections improving month on month, there are some pockets in states like West Bengal, Assam, Punjab and Maharashtra where collections are a little challenged, both on account of sluggish economic activity and mobility.
- Bank has observed a few external influences on customer prompting them not to pay, but it is still in very few pockets and not a trend.



# Q2FY21 Result Update@ Dalal&Broacha

Financials (Rs Bn)	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	YoY	QoQ	Q2FY21
Interest Earned	16.39	18.34	20.23	21.26	21.57	22.08	22.35	-2%	-7%	20.77
Interest Expended	9.84	10.95	12.05	12.57	12.35	11.87	11.94	-9%	-4%	11.45
NII	6.55	7.39	8.17	8.69	9.23	10.21	10.41	7%	-10%	9.32
Other Income	3.74	4.09	4.81	4.42	4.87	5.01	3.33	3%	37%	4.56
Total Income	20.13	22.43	25.04	25.68	26.44	27.09	25.68	-1%	-1%	25.33
Operating expenses	5.31	5.88	6.80	6.74	6.77	7.70	6.85	-1%	-2%	6.69
PPoP	4.98	5.60	6.19	6.36	7.32	7.52	6.90	13%	4%	7.20
Provisions	1.61	2.00	2.13	5.33	6.38	6.01	5.00	-1%	5%	5.26
Profit Before Tax	3.38	3.60	4.06	1.03	0.94	1.51	1.90	89%	2%	1.94
Тах	1.13	1.13	1.39	0.48	0.24	0.36	0.48	4%	3%	0.50
Net Profit	2.25	2.47	2.67	0.54	0.70	1.14	1.41	165%	2%	1.44
				Balance	sheet					
Net-worth	728	755	784	780	1055	1058	1072	39%	1%	1087
Deposits	5219	5839	6081	6283	6291	5781	6174	3%	4%	6451
Advances	4989	5431	5684	5848	5964	5802	5668	-4%	-1%	5616
Total assets	7220	8036	8405	8768	9146	8898	9245	6%	1%	9335
				Asset Q	uality					
GNPA (%)	1.39	1.38	1.38	2.60	3.33	3.62	3.45	73 bps	-11 bps	3.34
NNPA (%)	0.72	0.69	0.65	1.56	2.07	2.05	1.65	-18 bps	-26 bps	1.38
PCR (%)	49	51	53	41	39	44	53	1870 bps	624 bps	59
Capital adequacy										
Tier 1 Capital	12.5	12.1	11.3	11.3	15.0	15.3	15.2	386 bps	-3 bps	15.1
Tier 2 Capital	1.3	1.4	1.1	1.0	1.1	1.1	1.2	36 bps	18 bps	1.4
CRAR	13.8	13.5	12.4	12.3	16.1	16.4	16.4	422 bps	15 bps	16.5
RWA/Total Assets	78.1	74.2	78.2	76.4	74.5	75.7	74.3	-161 bps	49 bps	74.8

•••••



# Q2FY21 Result Update@ Dalal&Broacha

P&L (Rs Bn)	FY19	FY20E	FY21E	FY22E
Interest Earned	63.0	85.1	89.2	100.3
Interest Expended	37.6	48.8	50.3	54.0
NII	25.4	36.3	38.9	46.2
Other Income	14.4	19.1	20.4	23.3
Net Income	39.8	55.4	59.3	69.5
Operating expenses	20.4	27.9	30.1	34.4
PPoP	19.4	27.5	29.2	35.1
Provisions	6.4	20.0	21.0	17.6
Profit Before Tax	13.0	7.5	8.2	17.5
Tax	4.3	2.5	2.1	4.4
Net Profit	8.7	5.1	6.1	13.1

BS (Rs Bn)	FY19	FY20E	FY21E	FY22E
Equity	4	5	6	6
Reserves	71	101	121	132
Deposits	584	578	617	728
Borrowings	118	170	161	147
Other liabilities	26	36	32	37
Total liabilities	804	890	937	1049
Cash & Bank	66	85	110	96
Investments	168	181	190	203
Advances	543	580	598	708
Fixed Assets	4	4	5	6
Other Assets	22	38	35	37
Total Assets	804	890	937	1049

Ratios (%)	FY19	FY20E	FY21E	FY22E				
Growth								
NII	44	43	7	19				
PPOP	46	42	6	20				
PAT	37	-42	21	114				
Advances	35	7	3	18				
Deposits	33	-1	7	18				
Returns								
ROA	1.2	0.6	0.7	1.3				
ROE	12.2	5.6	5.3	9.9				

Ratios (%)	FY19	FY20E	FY21E	FY22E				
Asset Quality								
GNPA	1.38	3.62	4.56	3.38				
NNPA	0.69	2.05	1.64	1.11				
PCR	51	44	65	68				
	Per Share (Rs)							
EPS	20	10	10	22				
ABVPS	168	185	196	217				
P/E	9	18	17	8				
P/ABVPS	1.0	0.9	0.9	0.8				



# Q2FY21 Result Update@ Dalal&Broacha

#### Disclaimer

Dalal&Broacha Stock Broking Pvt Ltd, hereinafter referred to as D&B (CIN U67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services.

D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.dalal-broacha.com

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

## **Disclosures in respect of Research Analyst:**

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of	No
publication of Research Report:	
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served as officer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the	No
past twelve months	
Whether the Research Analyst has managed or co-managed public offering of securities for the	No
subject company in the past twelve months	
Whether the Research Analyst has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report	No



# Q2FY21 Result Update@ Dalal&Broacha

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Contact	Email ID	Contact No.	Sector
Mr. Kunal Bhatia	kunal.bhatia@dalal-broacha.com	022 67141442	Auto, Auto Ancillary, FMCG
Mrs.Charulata Gaidhani	charulata.gaidhani@dalal-broacha.com	022 67141446	Pharma /Healthcare
Mr. Mayank Babla	mayank.babladalal-broacha.com	022 67141412	I.T/Telecom/Media
Mr. Avinash Tanawade	avinash.tanawade@dalal-broacha.com	022 67141449	BFSI
Mr. Akshay Ashok	akshay.ashok@dalal-broacha.com	022 67141486	BFSI
Mr. Suraj Nandu	suraj.nandu@dalal-broacha.com	022 67141438	Associate

Address: - 508, Maker Chambers V, 221 Nariman Point, Mumbai 400 021

Tel: 91-22- 2282 2992, 2287 6173, Fax: 91-22-2287 0092

E-mail: research@dalalbroachaindia.com